Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Another Adverse Effect of the Opioid Epidemic: Hepatitis C Infections

Amid the ongoing opioid epidemic, hepatitis C virus (HCV) infection should be at the forefront of health care providers’ minds. Although HCV has been widely viewed as predominantly affecting baby boomers—those born between 1945 and 1965—a younger generation is experiencing increased incidence of infection.

Published
2 hours ago
From
Contagion Live
MSF challenges Gilead's undeserved patent in China on lifesaving hepatitis C medicine

The international medical humanitarian organization Doctors Without Borders/Médecins Sans Frontières (MSF) filed a legal patent challenge today at China’s State Intellectual Property Office (SIPO), requesting the invalidation of the patent it granted to US pharmaceutical corporation Gilead Sciences in 2012 for the oral hepatitis C medicine velpatasvir. This unmerited patent means this lifesaving medicine could remain priced out of reach for several more years, leaving millions of people to unnecessarily go without in China and abroad.

Published
2 hours ago
From
MSF press release
Just 12 countries worldwide on track to eliminate hepatitis C infection by 2030

Since the last global update in 2017, Italy, Spain, Switzerland, the UK and Mongolia have all been added to the list, thanks to the number of patients they treated in 2017, plus the lifting of treatment restrictions to include all patients with hepatitis C regardless of their degree of liver damage. These countries join the others already on track to eliminate by 2030: Australia, Egypt, France, Georgia, Iceland, Japan and the Netherlands. In all cases, these countries are treating at least 7% of their infected population each year, and have opened treatment up to all those infected.

Published
18 June 2018
From
CDA Foundation
Private Payers Deny Hepatitis C Drug Coverage to 52% of Members

Over half of private payer health plan beneficiaries were denied necessary hepatitis C drug coverage and prescriptions.

Published
14 June 2018
From
Health Payer Intelligence
10 patients safely receive hepatitis C-infected lungs in new clinical trial

Researchers behind a bold experiment to use hepatitis C-infected lungs for transplant say such organs could help address a critical shortage of donors and make “some good come out” of the increasing number of opioid-related deaths.

Published
14 June 2018
From
CTV
EATG launches a report on access to HCV-related services in the penitentiary system in Europe

Drawing on research on the state of access to services related to Hepatitis C in prison settings in Europe and Central Asia, which has highlighted major shortcomings across the countries as well as some promising practices in few countries, the European AIDS Treatment Group calls on national and prison authorities to scale up access to voluntary and confidential testing and counselling for people in detention.

Published
23 May 2018
From
EATG
Do direct acting antivirals cure chronic hepatitis C?

We were dismayed that the Editors of the BMJ presented the widely discredited Cochrane review of Hepatitis C virus therapy as mainstream opinion. It is not... There is no credible explanation for the fall in hepatitis C liver disease morbidity and mortality associated with the introduction of effective anti-virals other than the use of these drugs.

Published
18 May 2018
From
BMJ
Do fatigue and quality of life improve after hepatitis C is cured?

Patient-reported outcomes such as fatigue, vitality and mental health improve substantially in the two years following hepatitis C cure for people with cirrhosis, but people

Published
16 May 2018
By
Keith Alcorn
How states could be saving more hepatitis C patients

USC’s Neeraj Sood and colleagues propose an approach that leverages competition among drug manufacturers, saving states money and ensuring that more people get treatment

Published
15 May 2018
From
USC News
Collective Efforts By Civil Society Groups Bar The Way To Hepatitis C Patents

Many hold the view that Gilead’s revolutionary treatment against hepatitis C (sofosbuvir) marked the beginning of a shift in position toward the high prices of medicines, as high-income countries were also faced with an untenable burden to their health systems. In a number of lower and middle-income countries civil society organised itself to increase access to sofosbuvir for millions in need.

Published
14 May 2018
From
Intellectual Property Watch
← First12345...237Next →
Tell us why you visited aidsmap today
minimise

Could you help us by answering three questions on why you’ve visited aidsmap today?

You can close this questionnaire and come back to it later. Just click on the pink circle.

What prompted you to visit aidsmap today?

What exactly are you looking for? What specific questions do you need answered?

Have you found what you were looking for?

close

Thank you for your feedback

Thank you very much for taking time to fill in this questionnaire. NAM really values your feedback. It helps make the information we provide better.

If you have any other comments on the content of this website, we would be interested to hear from you. Please email info@nam.org.uk.

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.